From their meeting in April, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has published the highlights. During the meeting the CHMP announced recommendations for thirteen medicines for approval. Read more “Highlights from the April CHMP meeting”
Category: Medicinal product
MHRA updates its “final determinations on borderline products”
MHRA has published an updated list of final determinations issued by the Borderline division within the agency. Details of the product names, the names of the companies to whom the determination notices were issued and brief details of the reasons for the determination are provided. Read more “MHRA updates its “final determinations on borderline products””
Swissmedic updates guidance on orphan drugs and paediatric investigation plans
The Swiss Agency for Therapeutic Products (Swissmedic) has updated their guidance on orphan drugs and paediatric investigation plans (PIPs). Topics addressed include orphan drug fees and the documentation companies need to supply to support European and American PIPs. Read more “Swissmedic updates guidance on orphan drugs and paediatric investigation plans”
Highlights from the February CHMP meeting
From their meeting in February, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has published the highlights. During the meeting the CHMP announced the recommendations of eight medicines for approval, including two orphan medicines. For three out of the eight new medicines, the CHMP recommended a conditional marketing authorisation. Read more “Highlights from the February CHMP meeting”
Opioid Expert Working Group meets at MHRA
At the Medicines and Healthcare products Regulatory Agency (MHRA), an Expert Working Group (EWG) of the United Kingdom’s (UK’s) Commission on Human Medicines (CHM) met to begin reviewing the benefits and risks of opioid medicines, which includes dependence and addiction. Read more “Opioid Expert Working Group meets at MHRA”
EMA revises guideline on environmental risk assessment of human medicines
The updated European Medicines Agency (EMA) draft guideline on environmental risk assessment (ERA) now contains a decision tree which clarifies when ERA studies are required, and provides greater detail on technical guidance to help increase the consistency of the assessments. Performing an ERA is mandatory for any pharmaceutical company submitting a marketing authorisation application for a medicine. Read more “EMA revises guideline on environmental risk assessment of human medicines”
UK Government announces legalisation of medicinal cannabis
From 1st November 2018, patients in the United Kingdom (UK) can be prescribed medicinal cannabis by specialist doctors. These specialist doctors can legally issue prescriptions for cannabis-based medicines when they agree that their patients could benefit from this treatment. The law change has come after the Home Secretary listened to concerns from parents of children with conditions such as severe epilepsy. Read more “UK Government announces legalisation of medicinal cannabis”
First CAR-T therapies approved by European regulators
The first chimeric antigen receptor T-cell therapies (CAR-T), named Kymriah and Yescarta, have been approved by European regulators, enabling patients to access CAR-T therapies for the first time. Read more “First CAR-T therapies approved by European regulators”
Implementing ‘safety features’ under the Falsified Medicines Directive
Falsified medicines present a threat to public health in several ways, such as adverse reactions, interaction with other medicines and loss of faith in healthcare systems. Currently there is no mechanism that allows users to verify where a medicine has come from. The European Union (EU) Falsified Medicines Directive (FMD) aims to prevent falsified medicines from entering the legitimate supply chain and reaching patients. The ‘safety features’ policy requires a unique identifier and tamper-evident features to be added to prescription medicine packs by 9th February 2019. Read more “Implementing ‘safety features’ under the Falsified Medicines Directive”
EMA to open secure portal for orphan drug designations
The European Medicines Agency (EMA) is launching an online portal for orphan drug designations. The EMA wants sponsors to start using the portal from 19th June 2018, in anticipation of it becoming mandatory in three months’ time. Read more “EMA to open secure portal for orphan drug designations”